Palvella Therapeutics, Inc 8-K/A, filed Aug 31, 2023
Palvella Therapeutics, Inc. (PVLA)
8-K/A
2023-08-31
For: 2023-07-17
View Original
Added on
April 10, 2026
About this 8-K/A
Palvella Therapeutics, Inc filed this 8-K/A on August 31, 2023, reporting on events of July 17, 2023.
Items reported
- Item 2.05: Exit or restructuring costs
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 18, 2023 (July 17, 2023 )
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of
Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: 857 -246-8998
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
This Amendment No. 1 to the Current Report on Form 8-K/A (this “Amendment”) is being filed solely to amend the Current Report on Form 8-K, filed by Pieris Pharmaceuticals, Inc. (the "Company") with the Securities and Exchange Commission ("SEC") on July 18, 2023 (the “Original Report”), to provide an updated estimate of the total costs associated the Company's July 2023 reduction in force and restructuring (the "Workplace Restructuring"). No other changes have been made. The information contained in this Amendment does not reflect events occurring after the filing of the Original Report and does not modify or update the disclosures therein, except as specifically identified above.
Item 2.05 Costs Associated with Exit or Disposal Activities.
On August 30, 2023, the Compensation and Management Development Committee of the Board of Directors of the Company approved retention benefits for retained employees (other than executive officers) in connection with the Workplace Restructuring. As a result of the Workplace Restructuring, the Company expects to incur estimated retention benefits, severance and related costs of approximately $3.4 million through the second quarter of 2024. This is in addition to the estimated severance and other employee termination related costs reported on the Company's Form 8-K filed with the SEC on July 18, 2023.
The estimated charges that the Company expects to incur in connection with the Workplace Restructuring are subject to a number of assumptions, and actual results may differ materially from these estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Workplace Restructuring.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PIERIS PHARMACEUTICALS, INC.
|
|
|
Dated: August 31, 2023
|
/s/ Tom Bures
|
|
Tom Bures
|
|
|
Chief Financial Officer
|